Renaissance Technologies LLC Acquires 41,000 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Renaissance Technologies LLC boosted its stake in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 1.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,355,278 shares of the biopharmaceutical company's stock after acquiring an additional 41,000 shares during the quarter. Renaissance Technologies LLC owned 1.79% of Dynavax Technologies worth $30,077,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its position in shares of Dynavax Technologies by 96.5% during the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 1,169 shares during the period. Smartleaf Asset Management LLC raised its holdings in shares of Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 2,034 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Dynavax Technologies by 55.1% in the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock valued at $52,000 after purchasing an additional 1,457 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of Dynavax Technologies in the fourth quarter worth $71,000. Finally, Nisa Investment Advisors LLC boosted its holdings in Dynavax Technologies by 19.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock worth $83,000 after purchasing an additional 1,076 shares during the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have commented on DVAX shares. StockNews.com raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Monday, February 24th. The Goldman Sachs Group lowered Dynavax Technologies from a "neutral" rating to a "sell" rating and dropped their target price for the stock from $15.00 to $12.00 in a report on Tuesday, February 11th. William Blair reaffirmed an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, HC Wainwright reissued a "buy" rating and issued a $31.00 price objective on shares of Dynavax Technologies in a report on Friday, February 21st.

Dynavax Technologies Stock Performance

NASDAQ:DVAX traded down $0.14 during mid-day trading on Thursday, hitting $10.51. The stock had a trading volume of 1,159,743 shares, compared to its average volume of 2,210,968. The company's 50 day simple moving average is $13.08 and its 200 day simple moving average is $12.57. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of 58.39 and a beta of 1.26. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting analysts' consensus estimates of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The business had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. On average, equities research analysts forecast that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.